L’Oreal stock rating upgraded by JPMorgan on improving US market outlook

Published 31/07/2025, 08:34
L’Oreal stock rating upgraded by JPMorgan on improving US market outlook

Investing.com - L’Oreal SA (EPA:OR) (OTC:LRLCY), a personal care products leader with impressive gross profit margins of 74.2%, received a rating upgrade from JPMorgan, which raised the cosmetics giant from Underweight to Neutral while significantly increasing its price target to EUR360.00 from EUR290.00. According to InvestingPro analysis, the company maintains a "GREAT" financial health score.

The upgrade follows what JPMorgan described as a "mixed" second quarter of 2025, after which L’Oreal management expressed confidence that the global beauty market should grow 4% in fiscal year 2025, implying approximately 5% growth in the second half of the year. The company has demonstrated consistent shareholder returns, maintaining dividend payments for 34 consecutive years with a 19.7% dividend growth in the last twelve months.

JPMorgan cited an improving setup in the United States market as a key driver for the upgrade, noting that L’Oreal’s CEO expressed optimism about sequential acceleration in the US and potential benefits from tariffs-related pricing, though it remains unclear if the first half saw some pull-forward in demand.

The firm raised its second-half 2025 like-for-like growth forecast for L’Oreal to 4.7% from 4.0% previously, while maintaining its medium-term forecast of 4-5% like-for-like growth.

Despite the upgrade, JPMorgan noted that L’Oreal’s valuation remains ahead of peers at 29x PE26e and 18x EV/EBITDA26e (both excluding Sanofi (NASDAQ:SNY)), representing a premium that "remains elevated in the face of a MT growth rate of JPME 4-5%." Current metrics from InvestingPro show a P/E ratio of 32.7x and EV/EBITDA of 20.5x, with 10+ additional valuation insights available to Pro subscribers.

In other recent news, L’Oreal has announced plans to acquire a majority stake in the British skincare brand Medik8. This acquisition aligns with L’Oreal’s strategy to bolster its Luxe portfolio, with the company highlighting Medik8’s global potential due to its proven efficacy and accessible pricing. In addition to this strategic move, RBC Capital Markets has identified L’Oreal as one of its top picks in the Consumer Staples sector, alongside other notable companies such as AB InBev. However, Barclays (LON:BARC) has downgraded L’Oreal’s stock rating from Overweight to Underweight, citing concerns over the company’s growth trajectory. Barclays noted that L’Oreal’s beauty market outperformance has declined to 1.1 times, which is below its long-term averages. Despite these concerns, the company’s recent acquisition efforts and recognition by RBC Capital suggest a nuanced outlook for investors. These developments highlight the dynamic environment in which L’Oreal is operating.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.